Phase II study of pibenzimol in pancreatic cancer

Eric H. Kraut, T Fleming, James A. Neidhart, Brent C. Behrens, J. S. Macdonald

Investigational New Drugs · 1991 · 39 citations · 3 references

DOIFull text

Open access

Concepts

Abstract

Twenty-three patients with advanced pancreatic adenocarcinoma were treated with Pibenzimol utilizing a daily intravenous schedule for five days. There were no objective responses seen. The major toxicity was pancreatic with grade 3 hyperglycemia in eleven patients. Pibenzimol is inactive in patients with advanced pancreatic adenocarcinoma.

References

3